Humanin: Mitochondrial Peptide Against Alzheimer's and Aging

Humanin was discovered in 2001 in a remarkable way: researchers were screening gene fragments from the brains of Alzheimer's patients for sequences that could protect neurons from amyloid-beta toxicity. They found a 21-amino-acid peptide encoded within mitochondrial 16S ribosomal RNA that powerfully blocked neuronal death. They named it humanin. Two decades of research have since positioned it as one of the most promising mitochondria-derived peptides for aging and neurodegeneration.

Mechanism of Action

Humanin exerts cytoprotective effects through multiple mechanisms. The peptide binds to and neutralizes amyloid-beta oligomers — the toxic aggregates that drive Alzheimer's pathology — preventing them from triggering neuronal apoptosis. It also binds to BAX, a pro-apoptotic protein, blocking the mitochondrial apoptosis pathway.

At the cell surface, humanin acts through two known receptor systems: the formyl peptide receptor-like 1 (FPRL1) and a trimeric receptor complex involving CNTFR, WSX-1, and gp130. Through these receptors, humanin activates STAT3 and MAPK signaling cascades that promote cell survival.

Beyond direct cytoprotection, humanin improves insulin signaling, reduces inflammatory cytokines, and protects mitochondrial function — effects relevant to both neurodegeneration and metabolic aging.

Alzheimer's Disease Research

Humanin concentrations in the cerebrospinal fluid and brain tissue of Alzheimer's patients are significantly lower than in age-matched healthy controls, suggesting a role in disease progression. In multiple animal models of Alzheimer's — including APP/PS1 transgenic mice — humanin injection reduces amyloid plaque burden, improves cognitive performance, and extends survival.

The most potent humanin analog developed to date is HNG (humanin with Gly14-substitution), which is roughly 1,000-fold more potent than native humanin and has been used extensively in research models.

Metabolic and Cardiovascular Protection

Beyond neuroprotection, humanin exhibits insulin-sensitizing effects similar to MOTS-c, with which it shares mitochondrial origin. In obese mice, humanin reduces liver fat, improves glucose tolerance, and lowers circulating free fatty acids.

Cardiovascular research shows humanin protects cardiomyocytes from ischemia-reperfusion injury, reduces atherosclerotic lesion size in ApoE-knockout mice, and improves endothelial function. These effects suggest a broader cardioprotective role.

Aging and Longevity

Circulating humanin levels decline with age in both rodents and humans. Centenarians and their offspring have been found to have significantly higher humanin levels than age-matched controls — a finding from USC's Longevity Genes Project suggesting humanin may be a biomarker and mediator of exceptional longevity.

In C. elegans, humanin overexpression extends lifespan. In mice, HNG treatment extends median lifespan and improves healthspan markers including muscle function and cognitive performance.

Dosing and Administration

Research in rodents uses subcutaneous or intracerebroventricular doses typically in the 1-4 mg/kg range. Human clinical trials have not established a standard dose. Exploratory human research uses subcutaneous doses of 2-8 mg daily or several times per week.

The HNG analog is more potent and may be used at lower doses, though it is not naturally occurring. Native humanin degrades relatively quickly with a half-life of approximately 1-2 hours.

FAQ

Does humanin cross the blood-brain barrier? Peripherally administered humanin can reach the brain at low concentrations. Intranasal delivery is being investigated as a method to improve CNS penetration for neurological applications.

How do humanin levels decline with age? By middle age, circulating humanin levels in humans are approximately 50% of youthful levels. The decline correlates with the onset of metabolic and cognitive changes associated with normal aging.

Can humanin prevent Alzheimer's disease? Animal data are compelling, but no human prevention trials have been conducted. Humanin appears to be most effective against early-stage pathology and is unlikely to reverse advanced Alzheimer's.

Related Articles

• GHK-Cu (Copper Peptide): Skin Regeneration and Anti-Aging
• Klotho: The Anti-Aging Protein Peptide
• MOTS-c: Mitochondrial-Derived Peptide for Metabolism and Longevity
• Peptides for Energy: MOTS-c, Mitochondrial Peptides, and GH Axis
• Peptides for Longevity: Epithalon, SS-31, Humanin, and the Science

Track your supplements in Optimize.